Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy

J. D. Nosanchuk, A. Jeyakumar, A. Ray, E. Revskaya, Z. Jiang, R. A. Bryan, K. J.H. Allen, R. Jiao, M. E. Malo, B. L. Gómez, A. Morgenstern, F. Bruchertseifer, D. Rickles, G. B. Thornton, A. Bowen, A. Casadevall, E. Dadachova

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Metastatic melanoma remains difficult to treat despite recent approvals of several new drugs. Recently we reported encouraging results of Phase I clinical trial of radiolabeled with 188Re murine monoclonal IgM 6D2 to melanin in patients with Stage III/IV melanoma. Subsequently we generated a novel murine IgG 8C3 to melanin. IgGs are more amenable to humanization and cGMP (current Good Manufacturing Practice) manufacturing than IgMs. We performed comparative structural analysis of melanin-binding IgM 6D2 and IgG 8C3. The therapeutic efficacy of 213Bi- And 188Re-labeled 8C3 and its comparison with anti-CTLA4 immunotherapy was performed in B16-F10 murine melanoma model. The primary structures of these antibodies revealed significant homology, with the CDRs containing a high percentage of positively charged amino acids. The 8C3 model has a negatively charged binding surface and significant number of aromatic residues in its H3 domain, suggesting that hydrophobic interactions contribute to the antibody-melanin interaction. Radiolabeled IgG 8C3 showed significant therapeutic efficacy in murine melanoma, safety towards healthy melanin-containing tissues and favorable comparison with the anti-CTLA4 antibody. We have demonstrated that antibody binding to melanin relies on both charge and hydrophobic interactions while the in vivo data supports further development of 8C3 IgG as radioimmunotherapy reagent for metastatic melanoma.

Original languageEnglish (US)
Article number5466
JournalScientific Reports
Volume8
Issue number1
DOIs
StatePublished - Apr 3 2018

All Science Journal Classification (ASJC) codes

  • General

Cite this

Nosanchuk, J. D., Jeyakumar, A., Ray, A., Revskaya, E., Jiang, Z., Bryan, R. A., ... Dadachova, E. (2018). Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy. Scientific Reports, 8(1), [5466]. https://doi.org/10.1038/s41598-018-23889-z
Nosanchuk, J. D. ; Jeyakumar, A. ; Ray, A. ; Revskaya, E. ; Jiang, Z. ; Bryan, R. A. ; Allen, K. J.H. ; Jiao, R. ; Malo, M. E. ; Gómez, B. L. ; Morgenstern, A. ; Bruchertseifer, F. ; Rickles, D. ; Thornton, G. B. ; Bowen, A. ; Casadevall, A. ; Dadachova, E. / Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{b31100733fb847cb87e4b24d355358c3,
title = "Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy",
abstract = "Metastatic melanoma remains difficult to treat despite recent approvals of several new drugs. Recently we reported encouraging results of Phase I clinical trial of radiolabeled with 188Re murine monoclonal IgM 6D2 to melanin in patients with Stage III/IV melanoma. Subsequently we generated a novel murine IgG 8C3 to melanin. IgGs are more amenable to humanization and cGMP (current Good Manufacturing Practice) manufacturing than IgMs. We performed comparative structural analysis of melanin-binding IgM 6D2 and IgG 8C3. The therapeutic efficacy of 213Bi- And 188Re-labeled 8C3 and its comparison with anti-CTLA4 immunotherapy was performed in B16-F10 murine melanoma model. The primary structures of these antibodies revealed significant homology, with the CDRs containing a high percentage of positively charged amino acids. The 8C3 model has a negatively charged binding surface and significant number of aromatic residues in its H3 domain, suggesting that hydrophobic interactions contribute to the antibody-melanin interaction. Radiolabeled IgG 8C3 showed significant therapeutic efficacy in murine melanoma, safety towards healthy melanin-containing tissues and favorable comparison with the anti-CTLA4 antibody. We have demonstrated that antibody binding to melanin relies on both charge and hydrophobic interactions while the in vivo data supports further development of 8C3 IgG as radioimmunotherapy reagent for metastatic melanoma.",
author = "Nosanchuk, {J. D.} and A. Jeyakumar and A. Ray and E. Revskaya and Z. Jiang and Bryan, {R. A.} and Allen, {K. J.H.} and R. Jiao and Malo, {M. E.} and G{\'o}mez, {B. L.} and A. Morgenstern and F. Bruchertseifer and D. Rickles and Thornton, {G. B.} and A. Bowen and A. Casadevall and E. Dadachova",
year = "2018",
month = "4",
day = "3",
doi = "10.1038/s41598-018-23889-z",
language = "English (US)",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Nosanchuk, JD, Jeyakumar, A, Ray, A, Revskaya, E, Jiang, Z, Bryan, RA, Allen, KJH, Jiao, R, Malo, ME, Gómez, BL, Morgenstern, A, Bruchertseifer, F, Rickles, D, Thornton, GB, Bowen, A, Casadevall, A & Dadachova, E 2018, 'Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy', Scientific Reports, vol. 8, no. 1, 5466. https://doi.org/10.1038/s41598-018-23889-z

Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy. / Nosanchuk, J. D.; Jeyakumar, A.; Ray, A.; Revskaya, E.; Jiang, Z.; Bryan, R. A.; Allen, K. J.H.; Jiao, R.; Malo, M. E.; Gómez, B. L.; Morgenstern, A.; Bruchertseifer, F.; Rickles, D.; Thornton, G. B.; Bowen, A.; Casadevall, A.; Dadachova, E.

In: Scientific Reports, Vol. 8, No. 1, 5466, 03.04.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy

AU - Nosanchuk, J. D.

AU - Jeyakumar, A.

AU - Ray, A.

AU - Revskaya, E.

AU - Jiang, Z.

AU - Bryan, R. A.

AU - Allen, K. J.H.

AU - Jiao, R.

AU - Malo, M. E.

AU - Gómez, B. L.

AU - Morgenstern, A.

AU - Bruchertseifer, F.

AU - Rickles, D.

AU - Thornton, G. B.

AU - Bowen, A.

AU - Casadevall, A.

AU - Dadachova, E.

PY - 2018/4/3

Y1 - 2018/4/3

N2 - Metastatic melanoma remains difficult to treat despite recent approvals of several new drugs. Recently we reported encouraging results of Phase I clinical trial of radiolabeled with 188Re murine monoclonal IgM 6D2 to melanin in patients with Stage III/IV melanoma. Subsequently we generated a novel murine IgG 8C3 to melanin. IgGs are more amenable to humanization and cGMP (current Good Manufacturing Practice) manufacturing than IgMs. We performed comparative structural analysis of melanin-binding IgM 6D2 and IgG 8C3. The therapeutic efficacy of 213Bi- And 188Re-labeled 8C3 and its comparison with anti-CTLA4 immunotherapy was performed in B16-F10 murine melanoma model. The primary structures of these antibodies revealed significant homology, with the CDRs containing a high percentage of positively charged amino acids. The 8C3 model has a negatively charged binding surface and significant number of aromatic residues in its H3 domain, suggesting that hydrophobic interactions contribute to the antibody-melanin interaction. Radiolabeled IgG 8C3 showed significant therapeutic efficacy in murine melanoma, safety towards healthy melanin-containing tissues and favorable comparison with the anti-CTLA4 antibody. We have demonstrated that antibody binding to melanin relies on both charge and hydrophobic interactions while the in vivo data supports further development of 8C3 IgG as radioimmunotherapy reagent for metastatic melanoma.

AB - Metastatic melanoma remains difficult to treat despite recent approvals of several new drugs. Recently we reported encouraging results of Phase I clinical trial of radiolabeled with 188Re murine monoclonal IgM 6D2 to melanin in patients with Stage III/IV melanoma. Subsequently we generated a novel murine IgG 8C3 to melanin. IgGs are more amenable to humanization and cGMP (current Good Manufacturing Practice) manufacturing than IgMs. We performed comparative structural analysis of melanin-binding IgM 6D2 and IgG 8C3. The therapeutic efficacy of 213Bi- And 188Re-labeled 8C3 and its comparison with anti-CTLA4 immunotherapy was performed in B16-F10 murine melanoma model. The primary structures of these antibodies revealed significant homology, with the CDRs containing a high percentage of positively charged amino acids. The 8C3 model has a negatively charged binding surface and significant number of aromatic residues in its H3 domain, suggesting that hydrophobic interactions contribute to the antibody-melanin interaction. Radiolabeled IgG 8C3 showed significant therapeutic efficacy in murine melanoma, safety towards healthy melanin-containing tissues and favorable comparison with the anti-CTLA4 antibody. We have demonstrated that antibody binding to melanin relies on both charge and hydrophobic interactions while the in vivo data supports further development of 8C3 IgG as radioimmunotherapy reagent for metastatic melanoma.

UR - http://www.scopus.com/inward/record.url?scp=85045022949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045022949&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-23889-z

DO - 10.1038/s41598-018-23889-z

M3 - Article

C2 - 29615812

AN - SCOPUS:85045022949

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 5466

ER -